Literature DB >> 31904304

Effect of the Serious Illness Care Program on Health Care Utilization at the End of Life for Patients with Cancer.

Joanna Paladino1,2,3, Luca Koritsanszky1, Brandon J Neal1, Joshua R Lakin1,2,3,4, Jane Kavanagh1, Stu Lipsitz1,2, Erik K Fromme1,2,4, Justin Sanders1,2,4, Evan Benjamin1,2,3, Susan Block2,4,5, Rachelle Bernacki1,2,4.   

Abstract

Objectives: To determine the effect of the Serious Illness Care Program on health care utilization at the end of life in oncology. Design: Analysis of the secondary outcome of health care utilization as part of a cluster-randomized clinical trial that ran from 2012 to 2016. Clinicians in the intervention group received training, coaching, and system supports to have discussions with patients using a Serious Illness Conversation Guide (SICG); clinicians in the control arm followed usual care. Setting/Subject: Patients with advanced cancer who died within two years of enrollment at the Dana-Farber Cancer Institute. Measurement: Health care utilization was abstracted from the electronic medical record using the National Quality Forum (NQF)-endorsed indicators of aggressive cancer care at the end of life and scored from 0 to 6 (one point for each aggressive indicator); t tests and chi-square tests were used to determine differences between intervention and control patients.
Results: The charts of 159 patients who died were reviewed. Neither the main outcome of mean number of aggressive indicators (0.9 vs. 0.9, p = 0.84) nor the proportion of patients with any aggressive care (49% intervention [95% CI: 40-57] vs. 54% control [95% CI: 42-67]) differed between patients in the intervention and control groups.
Conclusion: In this analysis of a secondary outcome from a randomized clinical trial of the Serious Illness Care Program, intervention and control patients had similar end-of-life health care utilization as measured by the mean number of NQF-endorsed indicators. Future research efforts should focus on studying the strategies by which communication about patients' prognosis, values, and goals leads to personalized care plans.

Entities:  

Keywords:  end-of-life care; health care utilization; serious illness communication

Mesh:

Year:  2020        PMID: 31904304     DOI: 10.1089/jpm.2019.0437

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  6 in total

Review 1.  Interventions for interpersonal communication about end of life care between health practitioners and affected people.

Authors:  Rebecca E Ryan; Michael Connolly; Natalie K Bradford; Simon Henderson; Anthony Herbert; Lina Schonfeld; Jeanine Young; Josephine I Bothroyd; Amanda Henderson
Journal:  Cochrane Database Syst Rev       Date:  2022-07-08

2.  The effect of a palliative care pathway on medical interventions at the end of life: a pre-post-implementation study.

Authors:  Annemieke van der Padt-Pruijsten; Maria B L Leys; Esther Oomen-de Hoop; Agnes van der Heide; Carin C D van der Rijt
Journal:  Support Care Cancer       Date:  2022-09-07       Impact factor: 3.359

Review 3.  Patient Identification for Serious Illness Conversations: A Scoping Review.

Authors:  Rebecca Baxter; Erik K Fromme; Anna Sandgren
Journal:  Int J Environ Res Public Health       Date:  2022-03-31       Impact factor: 3.390

4.  Organizational readiness to implement the Serious Illness Care Program in hospital settings in Sweden.

Authors:  Sofia Andersson; Anna Sandgren
Journal:  BMC Health Serv Res       Date:  2022-04-22       Impact factor: 2.908

Review 5.  The Decision-Making Process for Palliative Sedation for Patients with Advanced Cancer-Analysis from a Systematic Review of Prospective Studies.

Authors:  Alazne Belar; Maria Arantzamendi; Johan Menten; Sheila Payne; Jeroen Hasselaar; Carlos Centeno
Journal:  Cancers (Basel)       Date:  2022-01-08       Impact factor: 6.639

6.  The Serious Illness Care Program in Oncology: Evidence, Real-World Implementation and Ongoing Barriers.

Authors:  Safiya Karim; Oren Levine; Jessica Simon
Journal:  Curr Oncol       Date:  2022-03-02       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.